Private company

Histogen Inc.

American pharmaceutical preparations company based in San Diego.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersSan Diego, United States
Incorporated inDE²
Business address10655 Sorrento Valley Road, Suite 200, San Diego, Ca 92121²
Filer categoryNon-accelerated filer, Smaller reporting company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-282.4%Operating margin³

-282.4%Net margin³

265.2%Revenue growth, 2022³

-73.9%Return on equity³

-$9.9MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development100¢$5.0M

Out of $3.8M in revenue.³ The company lost money this year.

Financial statements

Revenue⁴⁵⁶⁷³$3.8M in 2022+372% since 2016

Operating income⁴⁵⁶⁷³-$10.6M in 2022−64% since 2016

Net income⁴⁵⁷³-$10.6M in 2022−64% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Revenue	$799.0K⁴	$35.4M⁵	$33.6M⁵	$11.5M⁶	$2.1M⁷	$1.0M³	$3.8M³
Research and development	$20.3M⁴	$43.2M⁵	$41.4M⁵	$4.1M⁶	$6.2M⁷	$8.5M³	$5.0M³
Operating income	-$29.8M⁴	-$17.6M⁵	-$18.3M⁵	-$3.3M⁶	-$18.9M⁷	-$15.5M³	-$10.6M³
Interest	$70.0K⁴	$662.0K⁵	$696.0K⁵	$0⁵
Income tax				$0⁶	$0⁷	$0³	$0³
Net income	-$29.7M⁴	-$17.4M⁵	-$18.0M⁵	-$11.4M⁵	-$18.8M⁷	-$15.0M³	-$10.6M³
Earnings per share						-$7.79³	-$3.46³
Earnings per share (diluted)						-$7.79³	-$3.46³

Total assets¹⁰⁴⁵⁶⁷³$19.1M in 2022−77% since 2016

Total liabilities⁶⁷³$5.7M in 2022+210% since 2019

Shareholders’ equity⁵⁶⁷³$14.4M in 2022−34% since 2016

Cash⁴⁵⁶⁷³$12.1M in 2022−79% since 2016

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash	$58.1M⁴	$16.1M⁴	$11.6M⁵	$2.1M⁶	$6.8M⁷	$18.7M³	$12.1M³
Current assets	$80.5M¹⁰	$79.2M⁴	$47.4M⁵	$2.5M⁶	$8.4M⁷	$21.6M³	$13.5M³
Total assets	$82.3M¹⁰	$81.9M⁴	$48.8M⁵	$2.9M⁶	$15.0M⁷	$27.2M³	$19.1M³
Current liabilities	$39.6M¹⁰	$28.1M⁴	$18.5M⁵	$1.4M⁶	$2.8M⁷	$2.3M³	$1.2M³
Long-term debt					$369.0K⁷
Total liabilities				$1.8M⁶	$8.1M⁷	$7.1M³	$5.7M³
Shareholders’ equity	$21.8M⁵	$28.0M⁵	$27.4M⁵	-$37.1M⁶	$7.9M⁷	$21.2M³	$14.4M³
Shares outstanding	26.1M shares¹⁰	30.0M shares⁴	33.2M shares⁵	3.3M shares⁶	15.0M shares⁷	2.5M shares³	4.3M shares³

Cash from operations⁴⁵⁶⁷³-$9.7M in 2022

Capital spending⁴⁵⁶⁷³$216.0K in 2022+96% since 2016

Free cash flow⁴⁵⁶⁷³-$9.9M in 2022

Share buybacks⁴⁵$0 in 2019

Fiscal year	2016	2017	2018	2019	2020	2021	2022
Cash from operations	$27.0M⁴	-$33.2M⁵	-$34.9M⁵	-$1.3M⁶	-$12.1M⁷	-$14.5M³	-$9.7M³
Capital spending	$110.0K⁴	$25.0K⁵	$66.0K⁵	$152.0K⁶	$49.0K⁷	$241.0K³	$216.0K³
Free cash flow	$26.9M	-$33.2M	-$34.9M	-$1.4M	-$12.1M	-$14.8M	-$9.9M
Share buybacks	$0⁴	$11.2M⁵	$0⁵	$0⁵

Compare Histogen Inc. with another company

Leadership

Who has led Histogen Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

201520202025

Chief executive officerRichard W. Pascoe Dec 7, 2020 to Mar 30, 2021¹¹
Chief executive officerSteven J. Mento Jul 24, 2013 to Mar 14, 2023¹²
PresidentRichard W. Pascoe Dec 7, 2020 to Mar 30, 2021¹¹
PresidentSteven J. Mento Jul 24, 2013 to Mar 14, 2023¹²
Chief financial officerSusan A. Knudson Jan 15, 2021 to Mar 14, 2023¹³
Chief financial officerKeith W. Marshall Sep 1, 2017 to May 27, 2020¹⁴
Chief financial officerCharles Cashion Jul 24, 2013 to Feb 1, 2017¹⁵
Chief operating officerSusan A. Knudson Mar 14, 2023 to Mar 14, 2023¹⁶
Chief operating officerKeith W. Marshall Sep 1, 2017 to May 27, 2020¹⁴

Board members and other officers (29)

OfficerJoyce Reyes Jun 3, 2022 to Apr 28, 2023¹⁷
OfficerGail K. Naughton May 28, 2020 to Jan 15, 2021¹⁸
OfficerMartin Latterich May 28, 2020 to Feb 22, 2022¹⁹
OfficerRichard W. Pascoe May 28, 2020 to May 28, 2020²⁰
OfficerSusan A. Knudson May 29, 2020 to May 29, 2020²¹
OfficerMoya Daniels Oct 19, 2020 to Jan 15, 2021²²
SVP, Bus Dev, P&A MgmtDaniel L. Ripley Feb 2, 2017 to Feb 11, 2019²³
Vice President, FinanceMichelle L. Vandertie Apr 7, 2017 to Aug 1, 2019²⁴
EVP, Clinical DevelopmentDavid T. Hagerty Oct 3, 2014 to Feb 11, 2019²⁵
SVP, R&D and CSOAlfred P. Spada Jul 24, 2013 to Feb 27, 2023²⁶
Sr. VP, Clin. Res. & CMOGary C. Burgess Jul 24, 2013 to Feb 11, 2014²⁷
Board memberSusan Richards Windham-Bannister Mar 12, 2021 to Jun 21, 2023²⁸
Board memberRochelle Fuhrmann Mar 26, 2021 to Jun 21, 2023²⁹
Board memberBrian Satz May 28, 2020 to Jun 21, 2023³⁰
Board memberDavid Hugh Crean May 28, 2020 to Jun 21, 2023³¹
Board memberRichard W. Pascoe May 28, 2020 to Mar 30, 2021²⁰
Board memberStephen Chang May 28, 2020 to Oct 9, 2020³²
Board memberYizhuo Zhang May 28, 2020 to Oct 9, 2020³³
Board memberKathleen D. Scott Nov 19, 2019 to Nov 19, 2019³⁴
Board memberWilliam R. Larue Feb 7, 2017 to Jul 1, 2019³⁵
Board memberDaniel L. Kisner Feb 11, 2014 to Jun 21, 2023³⁶
Board memberPreston Klassen Feb 11, 2014 to Jul 1, 2019³⁷
Board memberDavid F. Hale Jul 24, 2013 to Jul 1, 2019³⁸
Board memberLouis P. Lacasse Jul 24, 2013 to Jun 15, 2015³⁹
Board memberMarc Olivier Perret Jul 24, 2013 to Aug 1, 2013⁴⁰
Board memberPaul H. Klingenstein Jul 24, 2013 to Feb 25, 2014⁴¹
Board memberShahzad Malik Jul 24, 2013 to Jun 27, 2016⁴²
Board memberSteven J. Mento Jul 24, 2013 to Mar 14, 2023¹²
Board memberWart Harold Van Jul 24, 2013 to Jul 1, 2019⁴³

Former names

Conatus Pharmaceuticals Inc.Aug 13, 2014 to May 21, 2020²
Conatus Pharmaceuticals IncNov 30, 2006 to Jun 23, 2014²

Timeline

Dec 7, 2020New chief executive Richard W. Pascoe becomes CEO¹¹
Jul 24, 2013New chief executive Steven J. Mento becomes CEO¹²
Jul 13, 2005Founded Histogen Inc. is founded⁴⁴

Filings

101 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 33 major events, 28 insider forms, 4 large holders, 1 private raises, 26 other. The latest 20:

Jan 4, 202415-12G EDGAR
Dec 15, 2023DEFA14A EDGAR
Dec 14, 2023425 EDGAR
Dec 14, 20238-K EDGAR
Dec 5, 2023425 EDGAR
Dec 5, 20238-K EDGAR
Nov 16, 2023S-8 POS EDGAR
Nov 16, 2023S-8 POS EDGAR
Nov 16, 2023S-8 POS EDGAR
Nov 16, 2023S-8 POS EDGAR
Nov 14, 2023DEFA14A EDGAR
Nov 9, 202310-Q EDGAR
Oct 18, 2023DEF 14A EDGAR
Oct 4, 2023PRE 14A EDGAR
Oct 3, 20238-K EDGAR
Sep 26, 20238-K EDGAR
Sep 18, 20238-K EDGAR
Aug 15, 20238-K EDGAR
Aug 10, 202310-Q EDGAR
Jul 5, 20238-K EDGAR

The 101 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 4 such filings since October 2021:

Feb 14, 2023SC 13G/A
Feb 8, 2023SC 13G/A
Feb 15, 2022SC 13G
Feb 11, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jul 14, 2022Raised $5 million in a private offering of securities Form D: 1 investor so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARHistogen Inc. filings on SEC EDGAR
2
SEC EDGARHistogen Inc. filings on SEC EDGAR
3
SEC EDGARHistogen Inc. 10-K for fiscal 2022
4
SEC EDGARHistogen Inc. 10-K for fiscal 2016
5
SEC EDGARHistogen Inc. 10-K for fiscal 2017
6
SEC EDGARHistogen Inc. 10-K for fiscal 2019
7
SEC EDGARHistogen Inc. 10-K for fiscal 2020
8
SEC EDGARHistogen Inc. 10-Q for fiscal 2023
9
SEC EDGARHistogen Inc. 10-Q for fiscal 2023
10
SEC EDGARHistogen Inc. 10-K for fiscal 2016
11
SEC EDGARRichard W. Pascoe, Chief executive officer
12
SEC EDGARSteven J. Mento, Chief executive officer
13
SEC EDGARSusan A. Knudson, Chief financial officer
14
SEC EDGARKeith W. Marshall, Chief financial officer
15
SEC EDGARCharles Cashion, Chief financial officer
16
SEC EDGARSusan A. Knudson, Chief operating officer
17
SEC EDGARJoyce Reyes, Officer
18
SEC EDGARGail K. Naughton, Officer
19
SEC EDGARMartin Latterich, Officer
20
SEC EDGARRichard W. Pascoe, Officer
21
SEC EDGARSusan A. Knudson, Officer
22
SEC EDGARMoya Daniels, Officer
23
SEC EDGARDaniel L. Ripley, SVP, Bus Dev, P&A Mgmt
24
SEC EDGARMichelle L. Vandertie, Vice President, Finance
25
SEC EDGARDavid T. Hagerty, EVP, Clinical Development
26
SEC EDGARAlfred P. Spada, SVP, R&D and CSO
27
SEC EDGARGary C. Burgess, Sr. VP, Clin. Res. & CMO
28
SEC EDGARSusan Richards Windham-Bannister, Board member
29
SEC EDGARRochelle Fuhrmann, Board member
30
SEC EDGARBrian Satz, Board member
31
SEC EDGARDavid Hugh Crean, Board member
32
SEC EDGARStephen Chang, Board member
33
SEC EDGARYizhuo Zhang, Board member
34
SEC EDGARKathleen D. Scott, Board member
35
SEC EDGARWilliam R. Larue, Board member
36
SEC EDGARDaniel L. Kisner, Board member
37
SEC EDGARPreston Klassen, Board member
38
SEC EDGARDavid F. Hale, Board member
39
SEC EDGARLouis P. Lacasse, Board member
40
SEC EDGARMarc Olivier Perret, Board member
41
SEC EDGARPaul H. Klingenstein, Board member
42
SEC EDGARShahzad Malik, Board member
43
SEC EDGARWart Harold Van, Board member
44
gleifHistogen Inc. is founded